Literature DB >> 16557455

Pharmacokinetics and excretion of hydroxysafflor yellow A, a potent neuroprotective agent from safflower, in rats and dogs.

Dafeng Chu1, Wanhui Liu, Zhuo Huang, Shengsheng Liu, Xueqi Fu, Ke Liu.   

Abstract

Studies were conducted to characterize the pharmacokinetics and excretion of hydroxysafflor yellow A (HSYA) in rats and dogs after administration by intravenous injection or infusion. Plasma, urine, feces and bile concentrations of HSYA were measured using five validated mild HPLC methods. Linear pharmacokinetics of HSYA after the intravenous administrations were found at doses ranging from 3 to 24 mg/kg in rats and from 6 to 24 mg/kg in dogs. At a dose of 3 mg/kg, HSYA in urine, feces and bile was determined. For 48 h after dosing, the amount of urinary excretion accounted for 52.6 +/- 17.9 % (range: 31.1 - 78.7%, n = 6) of the dose, and the amount of fecal amount accounted for 8.4 +/- 5.3% (range 1.7 - 16.4%, n = 6) of the dose. Biliary excretion amount accounted for 1.4 +/- 1.0% (range 0.4-2.9%; n = 6) of the dose for 24 h after dosing. Percent plasma protein binding of HSYA ranged from 48.0 to 54.6% at 72 h. In summary, five mild HPLC methods for the determinations of HSYA in rat plasma, urine, feces, bile and dog plasma have been developed and successfully applied to preclinical pharmacokinetics and excretion of HSYA in rats and dogs. The results of excretion studies indicated that HSYA was rapidly excreted as unchanged drug in the urine. In view of previous pharmacological work, the concentration-dependent neuroprotective effect of HSYA in rats was defined.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16557455     DOI: 10.1055/s-2005-916249

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  5 in total

1.  Pharmacokinetic Studies of Oxathio-Heterocycle Fused Chalcones.

Authors:  Krystyna Okoniewska; Marek T Konieczny; Krzysztof Lemke; Tomasz Grabowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

2.  Hydroxysafflor Yellow A Attenuates the Apoptosis of Peripheral Blood CD4+ T Lymphocytes in a Murine Model of Sepsis.

Authors:  Jinping Wang; Ping Wang; Shuiqing Gui; Yun Li; Runhua Chen; Renqing Zeng; Peiyan Zhao; Hanwei Wu; Zheyu Huang; Jianlong Wu
Journal:  Front Pharmacol       Date:  2017-09-06       Impact factor: 5.810

3.  Effects of Hydroxysafflor Yellow A on the PI3K/AKT Pathway and Apoptosis of Pancreatic β-Cells in Type 2 Diabetes Mellitus Rats.

Authors:  Maosheng Lee; Huilin Li; Hengxia Zhao; Miao Suo; Deliang Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2020-04-09       Impact factor: 3.168

4.  Protective Effect of Hydroxysafflor Yellow A on Nephropathy by Attenuating Oxidative Stress and Inhibiting Apoptosis in Induced Type 2 Diabetes in Rat.

Authors:  Maosheng Lee; Hengxia Zhao; Xuemei Liu; Deliang Liu; Jianping Chen; Zengying Li; Shufang Chu; Xinhui Kou; Si Liao; Yuxiu Deng; Huilin Li; Weidong Xie
Journal:  Oxid Med Cell Longev       Date:  2020-03-11       Impact factor: 6.543

5.  Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles.

Authors:  Liang-Zhong Lv; Chen-Qi Tong; Jia Yu; Min Han; Jian-Qing Gao
Journal:  Int J Nanomedicine       Date:  2013-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.